Alnylam Pharmaceuticals Inc
SWB:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
SWB:DUL
|
US |
|
P
|
Protalix Biotherapeutics Inc
AMEX:PLX
|
US |
|
SPAR Group Ltd
OTC:SGPPF
|
ZA |
|
Sanlorenzo SpA
MIL:SL
|
IT |
|
T
|
Turning Point Brands Inc
F:0T5
|
US |
|
F
|
First Majestic Silver Corp
SWB:FMV
|
CA |
|
Vianet Group PLC
F:AS2
|
UK |
|
M
|
Merck & Co Inc
XMUN:6MK
|
US |
|
M
|
Muenchener Rueckversicherungs Gesellschaft in Muenchen AG
XMUN:MUV2
|
DE |
|
Y
|
Yankuang Energy Group Co Ltd
XMUN:YZC
|
CN |
|
A
|
African Rainbow Minerals Ltd
JSE:ARI
|
ZA |
|
NTG Nordic Transport Group AS
F:NRSA
|
DK |
|
C
|
CNH Industrial NV
XMUN:37C
|
UK |
|
K
|
Kinder Morgan Inc
XMUN:2KD
|
US |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 327.75 EUR with a low forecast of 201.6 EUR and a high forecast of 515.76 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
327.75
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 327.75 EUR with a low forecast of 201.6 EUR and a high forecast of 515.76 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 18%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
19%
The compound annual growth rate for Gross Profit over the next 8 years is 19%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
37%
The compound annual growth rate for Operating Income over the next 8 years is 37%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
91%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 91%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
40%
The compound annual growth rate for Net Income over the next 8 years is 40%.
